Barinthus Biotherapeutics (BRNS) Earnings Date & Reports

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

BRNS is expected to report earnings to fall 28.76% to -36 cents per share on May 08

Barinthus Biotherapeutics BRNS Stock Earnings Reports

Q1'25

Est.

$-0.36

Q4'24

Missed

by $0.05

Q3'24

Beat

by $0.23

Q2'24

Missed

by $0.03

Q1'24

Beat

by $0.14

The last earnings report on March 20 showed earnings per share of -50 cents, missing the estimate of -45 cents. With 6.42K shares outstanding, the current market capitalization sits at 42.36M.

View a ticker or compare two or three

Compare

BRNS